Zogenix Gets the Thumbs-Down

Shares of Zogenix (NASDAQ: ZGNX  ) fell 45% after a Food and Drug Administration advisory committee reviewing its extended-release painkiller Zohydro voted 11-2 against the drug. Much of the resistance from the committee focused on potential abuse of the drug, and Zohydro in its current form is not crush-resistant. In this video, Motley Fool health care bureau chief Brenton Flynn tells us why this is such a devastating blow for the company, and what, if anything, in Zogenix's pipeline may save it.

Zogenix is a prime example of the big losses you can experience investing in unproven biotech stocks. That's why here at The Motley Fool we believe the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 10, 2012, at 5:00 PM, kthor wrote:

    actually Zogenix has a product with less adverse effects than what's available ... has the ability to be abused by patients, but so does the competition it might possible replaced with less adverse effect on a organ ... the panel shows how corrupt they are ... chk their offshore accounts LOL

  • Report this Comment On December 10, 2012, at 6:22 PM, muhamedikbar wrote:

    purdue pharma must have had deeper pockets and more influence on the panel than zogenix did....

    meanwhile, pain sufferers....actual pain from cancer, or debilitating diseases, and not just clowns with a tooth ache or pulled muscle....can't get pain relief they need. Oxycontin, aka purdue pharma, had to change their formula because the FDA came down on them so hard for all issues they had with abuse (i.e. crushing, snorting, and shooting)....who in their right mind would have thought the government would okay Zohydro? A drug like what oxycontin was prior to purdue being required to make the tamper and abuse resistant changes they were told to make, or quit making it. Only way zohydro get approved, make it witht he same stuff oxycontin is made from where it can't be crushed. It's an option, but it won't be any bette than whats already out there...why would people switch?

  • Report this Comment On January 17, 2013, at 1:10 PM, trismigistus wrote:

    What the public does not understand is ever since the reformulation of Oxycontin and Opana the drugs no longer work for legitamate patients.

    They are little more than placebo's.

    People who suffer from chronic pain have had to go back to using liver damaging Vicodin, or the generic forms of it.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2147159, ~/Articles/ArticleHandler.aspx, 10/23/2016 11:31:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ZGNX $9.35 Up +0.25 +2.75%
Zogenix CAPS Rating: **
COV.DL $0.00 Down +0.00 +0.00%
Covidien CAPS Rating: *****